Please login to the form below

Not currently logged in
Email:
Password:

Nycomed wins EC approval for Instanyl

The EC has granted Nycomed marketing authorisation for its Instanyl single-dose nasal spray

The European Commission (EC) has granted Nycomed marketing authorisation for its Instanyl single-dose nasal spray.

The spray is approved for the management of breakthrough pain in cancer patients, and was first approved in Europe as a multi-dose nasal spray in 2009.

The launch of the single-dose spray will provide greater flexibility to the patient and help to manage dose titration and dose modification, as well as enabling easier tracking of patient's use of rescue medication, according to Nycomed.

Guido Oelkers, executive vice president at the company, said: "Development of the Instanyl single-dose nasal spray further demonstrates Nycomed's commitment to innovation in areas of clear medical need. Over half a million cancer patients are suffering from breakthrough pain in Europe. The Instanyl single-dose nasal spray will add flexibility to the managing of their pain."

The single-dose nasal spray will be available in 50 µg, 100 µg, and 200 µg doses.

4th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics